FRANKFURT - CureVac has recently shared encouraging outcomes from its latest COVID-19 vaccine trials, conducted in partnership with GSK. The preliminary data indicates that the vaccines, including a monovalent and a bivalent candidate, have generated strong immune responses even with lower dosages and are well-tolerated.

The monovalent vaccine candidate is designed to target the spike protein of the Omicron BA.4-5 variant, whereas the bivalent vaccine candidate aims at the spike proteins of both the Omicron BA.4-5 variant and the original SARS-CoV-2 virus. These results mark a significant step forward in the ongoing efforts to develop effective vaccines against emerging variants of COVID-19.

As the company announces these positive trial results, it is also preparing for discussions about advancing to a Phase 3 trial. This next phase is crucial for further evaluating the efficacy and safety of the vaccine candidates on a larger scale. The progression to Phase 3 will bring the vaccines one step closer to potential approval and public availability.

https://www.investing.com/news/cryptocurrency-news/curevac-reports-promising-covid19-vaccine-trial-results-with-gsk-93CH-3268208